[SCHEDULE 13G] Cullinan Therapeutics, Inc. Passive Investment Disclosure (>5%)
Rhea-AI Filing Summary
Cullinan Therapeutics ownership disclosure by Kynam Capital group. The filing reports that Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang beneficially own 3,114,132 shares of Cullinan Therapeutics common stock, equal to 5.27% of the class as of 12/31/2025.
The disclosure lists shared voting and dispositive power of 3,114,132 shares and zero sole voting or dispositive power. The report includes the issuer CUSIP 230031106 and the filer address in Princeton, New Jersey.
Positive
- None.
Negative
- None.
Insights
Beneficial ownership position and voting/dispositive structure are disclosed precisely.
The excerpt shows a 3,114,132 share holding representing 5.27% of common stock as of 12/31/2025. The three filing parties report shared voting and dispositive power and report zero sole voting or dispositive power.
Timing and size are explicit; subsequent filings would show changes. Cash‑flow treatment and any planned transactions are not stated in the provided excerpt.
Filing clarifies control attribution across fund, GP and individual filer.
The filing attributes the same 3,114,132 shares to Kynam Capital Management, GP, and Yue Tang, indicating shared authority rather than individual sole control. The CUSIP 230031106 and issuer address are provided for identification.
Ownership percentages and power breakdowns are binding disclosures for regulatory tracking; no change-in-control or transaction intent is stated in the excerpt.